A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03016091 |
|
Recruitment Status : Unknown
Verified January 2019 by Rabin Medical Center.
Recruitment status was: Recruiting
First Posted : January 10, 2017
Last Update Posted : April 18, 2019
|
Sponsor:
Rabin Medical Center
Information provided by (Responsible Party):
Rabin Medical Center
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Unknown |
|---|---|
| Estimated Primary Completion Date : | February 2020 |
| Estimated Study Completion Date : | February 2022 |